1. DDHS Panel on Antiretoviral Guidelines for Adult & Adolescents, (2006), Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Office of AIDS Research Advisory Council. AIDS Info/US Department of Health and Human Services.
2. Ait-Khaled, M., Rakik, A., Griffin, P., Stone, C., Richards, N., Thomas, D., Falloon, J. and Tisdale, M., (2003), HIV-1 reverse transcriptase and protease resistance mutations selected during 16–72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. Antivir Ther, 8, 111–120.
3. Ait-Khaled, M., Stone, C., Amphlett, G., Clotet, B., Staszewski, S., Katlama, C. and Tisdale, M., (2002), M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. AIDS, 16, 1686–1689.
4. Alexander, C.S., Montessori, V., Wynhoven, B., Dong, W., Chan, K., O’Shaughnessy, M.V., Mo, T., Piaseczny, M., Montaner, J.S. and Harrigan, P.R., (2002), Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antivir Ther, 7, 31–35.
5. Allen, T.M. and Altfeld, M., (2003), HIV-1 superinfection. J Allergy Clin Immunol, 112, 829.